Bayer has overturned a ruling that it brought discredit on the pharma industry. | Bayer has overturned a ruling that it ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are ...

For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA HD and EYLEA. Regeneron (NASDAQ: REGN) is a leading biotechnology company that ...

As the first-to-file interchangeable biosimilar to Eylea, Yesafili affirms our scientific strength ... and routes of administration described in its full prescribing information.

It is highly similar to the reference product Eylea® (aflibercept ... of administration described in its Full Prescribing Information. About YESAFILI: The approval for YESAFILI (aflibercept ...

It is highly similar to the reference product Eylea® (aflibercept ... of administration described in its Full Prescribing Information.

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) ...

PULSAR in wAMD and PHOTON in DME/diabetic retinopathy (DR) are double-masked, active-controlled pivotal trials that were conducted in multiple centers globally. In both trials, patients were ...

AVT06/AVT29 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept ... Please click here for full Prescribing Information for SELARSDI. Teva Pharmaceutical Industries ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , and Alvotech today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDItm (ustekinumab-aekn) ...